DexCom, Inc.
http://www.dexcom.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DexCom, Inc.
Finance Watch: Three New IPOs, But Three Hopefuls Hold Back
IPO Edition: Caribou, AbSci and HCW launched initial public offerings, but three firms that were expected to go public during the week of 19-23 July did not, raising the question of whether investors are beginning to pull back from biopharma offerings.
Digital Health Roundup, June 2021: Winners In Record-Breaking H1 Digital Health Funding; ADA 2021; Telehealth Update
In this roundup feature focusing on the developments in digital health, we highlight the key news and announcements from June.
Finance Watch: The Bigger The Better? Erasca, Imago Rise After IPOs
Public Company Edition: Three $100m-plus US initial public offerings launched on 15 July after two smaller biopharma IPOs earlier in the month. Also, Gelesis announced a SPAC merger, Brii and Amniotics launched ex-US IPOs, and Intellia, Cerevel and Kymera priced large follow-on offerings.
Dexcom, Abbott File Dueling Lawsuits On Diabetes Management Technology
The two suits address a total of 17 patents on elements of continuous glucose monitors, or CGMs.
Company Information
- Industry
-
Medical Devices
- Monitoring Equipment & Devices
-
In Vitro Diagnostics
- Biosensors
- Glucose Testing
- Other Names / Subsidiaries
-
- SweetSpot Diabetes Care
- TypeZero Technologies, LLC